Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.60 |
| ▸ | ESR1 | P03372 | 4/20 | 0.60 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.56 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440804 | 0.90 | ESR2 (0.62) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6438788 | 0.89 | ESR2 (0.62) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6440445 | 0.89 | CNR2 (0.53) | ESR2ESR1ROCK2RPS6KA5MAP4K4 | |
| SCHEMBL7061814 | 0.81 | ESR2 (0.77) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6445980 | 0.80 | ESR2 (0.71) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6441554 | 0.80 | ALDH1A1 (0.61) | ESR2ESR1RPS6KB1ROCK1MAPT | |
| SCHEMBL6439134 | 0.79 | ESR2 (0.66) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6438803 | 0.79 | ESR2 (0.62) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6439148 | 0.79 | ESR2 (0.62) | ESR2ESR1GRIA1CACNG8CACNG2 | |
| SCHEMBL6439809 | 0.79 | MDM2 (0.48) | ESR2ESR1GRIA1CACNG8CACNG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | claimed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1517897-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2004000817-A2 | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002524-A1 | Benzimidazole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | ESR2 3/4885ESR1 1/4885GRIA1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.